Paper-Based and Smartphone-Based Memory Supports
Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the ability to remember future intentions such as taking medications at a given time. Prior interve
| Condition(s) | Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the ability to remember future intentions such as taking medications at a given time. Prior intervention studies that targeted prospective memory used mnemonic strategies or cognitive training, but these approaches resulted in modest gains in clinical populations. By contrast, a Stage I pilot trial indicated that smartphone-based memory aids (reminder apps) can be accepted and used by persons with mild cognitive impairment and mild dementia to improve both subjective and objective prospective memory performance. The investigators will now test for efficacy, durability, and |
| Who can participate | Inclusion Criteria: * Demonstrate capacity to consent via structured interview that involves reviewing core study features and probing for understanding of potential benefits/consequences of participating, and understanding that one can withdraw consent at any point, or availability to obtain surrogate consent. * Clinical features consistent with a diagnosis of MCI or dementia. For clinic-referred participants, available records will be reviewed to ensure the clinical diagnosis meets published diagnostic guidelines. If there is not sufficient documentation for diagnostic purposes, then semi-structured clinical interview and cognitive screening (see below) will be reviewed by clinical staff. * Cognitive status for inclusion will be assessed by Montreal Cognitive Assessment (MoCA) scores of |
| Ages | 50 Years |
| Sex | All |
| Lead sponsor | Baylor University |
| Locations | Austin, Texas, United States; Temple, Texas, United States; Waco, Texas, United States |
| Start date | 2024-06-27 |
| NCT ID | NCT06444841 |
| Official listing | https://clinicaltrials.gov/study/NCT06444841 |